Ring's novel vector Anellogy™ platform harnesses unique properties of anelloviruses to create a pipeline of redosable vectors compatible with the human immune system to target specific tissues Ring's platform is the first disruptive advance in gene therapy in more than 50 years, since the discovery of AAV Ring has built the world's first and only vertically integrated anellovirus database with thousands of newly discovered vector candidates to produce programmable medicines C

Combination aims to transform the genomics landscape and deliver a differentiated product offering into high growth clinical markets Brings together Omniome’s high accuracy short-read sequencing platform, with PacBio’s market leading, high accuracy long-read solutions Transaction supported by concurrent $300 million PIPE financing from premier life science investors MENLO PARK, Calif. and SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Na